A reliable multigram synthesis of (±) doxazosin

Organic Preparations and Procedures International

Volumn 35, Issue 6, 2003, Pages 603-608

  Kumaraswamy, G ^a   Das, A K ^a   Jena, Nivedita ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; MULTIGRAM SYNTHESIS;

CARBOXYLIC ACID DERIVATIVE; DOXAZOSIN; ETHYL 2,3 DIHYDROBENZO[1,4]DIOXIN 2 CARBOXYLATE; N (2,3 DIHYDRO[1,4]DIOXIN 2 CARBONYL)PIPERAZINE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS;

EID: 0942300590     PISSN: 00304948     EISSN: 19455453     Source Type: Journal    
DOI: 10.1080/00304940309355360     Document Type: Article

References (24)

1. Drugs Future 25, 1311 (2000).
2. R. M. Guthrie and R. L. Siegel, Clin. Ther., 21, 1732 (1999).
3. L. Elliot, P. A. Meredith, and J. L. Reid, Am. J. Cardiol., 59, 79G (1987).
4. R. S. Kirby, Int. J. Clin. Pract., 52, 402 (1998).
5. T. H. Althuis and H. J. Hess, J. Med. Chem., 20, 146 (1977).
6. P. M. Manoury, J. L. Binet, A. P. Dumas, F. Lefevre-Borg, and I. Cavero, J. Med. Chem., 29, 1925 (1986).
7. F. R. Buhler, F. W. Amann, P. Bolli, L. Hulthen, W. Kiowski, R. Landmann, and E. Burgisser, J. Cardiovasc. Pharmacol., 4, S134 (1982).
8. D. S. Goldstein, Hypertension, 5, 86 (1983).
9. S. F. Campbell, M. J. Davey, J. D. Hardstone, B. N. Lewis and M. J. Palmer, J. Med. Chem., 30, 49-57 (1987).
10. Q. Kevin Fang, P. Grover, Z. Han, F. X. McConville, R. F. Rossi, D. J. Olsson, D. W. Kessler, S. A. Wald, and C. H. Senanayake, Tetrahedron: Asymm., 12, 2169 (2001).
11. S. F. Campbell, UK Patent 2, 007, 656B; CA, 91: 74649u (1979).
12. S. F. Campbell, US Patent 4, 188, 390; CA, 91: 74649u (1999).
13. H-J. Hess, US Patent 3, 511, 836; CA, 71: 91519f (1969).
14. Koo, S. Avakian, and G. J. Martin, J. Am. Chem. Soc., 77, 5373 (1955).
15. Arrault, G. Guillaumet, J-M. Leger, J. Christian and J-Y. Merour, Synthesis. 13, 1879 (2002).
16. The purity of the product (±) (3) was determined by GC and found to be 98% (5% OV-17, 100-250°C, 10 °C /min).
17. The US and Indian patent applications are under review (CSIR Ref. No. NF/538/01).
18. W-C. Chou, C-W. Tan, S. F. Chen, and H. Ku. J. Org. Chem. 63, 10015 (1998).
19. Polymorphic form of doxazosin mesylate (Form I), US Patents 6, 130, 218; CA, 129: 45312b (1998) and 6, 140, 334; CA, 129: 45310z (1998).
20. The purity of the product (±) 4 was monitored by NMR and TLC. The NMR spectrum shows no trace of the hw-amide. We were unable to obtain a HPLC analysis of the product (±) 4 using YMC ODS 25cms, 5(1) column (50:50 mixture of acetonitrile and methanol modified with 0.05% v/v TEA in water).
21. The US and Indian patent applications are under review (CSIR Ref. No. NF/428/02). European Patent No. 02021686.7
22. Process optimization for the direct resolution of (±) 4 is in progress.
23. The current ICH guideline for residual solvents in pharmaceutical active substances (ICH Guideline: Residual Solvents, Pharmeuropa, Vol. 8, No. 1, page 103, March 1996).
24. A 100-kg batch production of this drug is currently under progress with Cadila Pharmaceuticals Ltd. Ahmedabad-380 009, Gujarat, India.